Compare Msci Inc (MSCI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Recursion Pharmaceuticals Inc — how do they compare? Msci Inc trades at $562.94 (market cap $45.51B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Msci Inc is far larger — about 29.7× Recursion Pharmaceuticals Inc's market cap, and Msci Inc pays a 1.31% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MSCI | RXRX | |
|---|---|---|
Market Cap | $45.51B | $1.53B |
Sector | Financials | Health |
52-Week High | $643.83 | $6.79 |
52-Week Low | $511.84 | $2.84 |
Enterprise Value | $51.67B | $946.50M |
Dividend Yield | 1.31% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
